STAT

OCTOBER 8, 2023

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions. Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years

132

132

Fierce Healthcare

OCTOBER 8, 2023

LAS VEGAS—As HLTH 2023 kicks off, the next four days will be buzzing with hype over digital health and virtual care innovations. | The Peterson Health Technology Institute aims to raise the bar in digital health by providing independent, evidence-based assessments of emerging products, something that is currently lacking in the market.

124

124

STAT

OCTOBER 8, 2023

Venture firms, convinced they’re jumpstarting the world’s most helpful tech products, have struggled mightily to get them in the hands of cash-strapped, risk-averse hospital administrators and clinicians — but that could change as tech startups and their powerful backers explore ever closer relationships with health care providers.

Hospitals 131

Hospitals 131

Fierce Pharma

OCTOBER 8, 2023

After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. | After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the KRAS drugmaker.

118

118

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Med Ed 101

OCTOBER 8, 2023

I received a question the other day about EPT (expedited partner therapy) and STD management. State laws vary so be sure to check with your board of pharmacy. In this blog post, we will describe EPT and share what we have learned when looking at the rules from two different states. EPT. What is it? Chances […] The post EPT and Sexually Transmitted Disease Management appeared first on Med Ed 101.

104

104

Fierce Healthcare

OCTOBER 8, 2023

LAS VEGAS—The HLTH 2023 conference kicked off Sunday expecting to draw up to 10,000 attendees from across the industry to plot the future of digital health innovation. | The latest news and updates from the HLTH 2023 conference: Uber and Optum team up to simplify access to Medicare Advantage supplemental benefits.

81

81

Fierce Healthcare

OCTOBER 8, 2023

Value-based care company Main Street Health is charting an expansion into eight additional states as it banks more than $315 million in new capital. | Value-based care company Main Street Health is charting an expansion into eight additional states as it banks more than $315 million in new capital.

68

68

The FDA Law Blog

OCTOBER 8, 2023

By Karla L. Palmer — On Friday, October 6, 2023, DEA announced a second extension of telemedicine flexibilities concerning the prescribing of controlled substances, which were originally set to expire after the end of the COVID-19 pandemic emergency. As a reminder, back in February 2023, HPM blogged about DEA’s two proposed rules for prescribing (1) controlled substances generally and (2) for buprenorphine use in opioid treatment.

Controlled Substances 64

Controlled Substances 64

PharmExec

OCTOBER 8, 2023

It’s with a heavy heart that I share my departure from Pharmaceutical Executive.® It’s hard to believe that one year ago (in September 2022) I began my journey with the team here and the publication (and with all of you!). First and foremost, a huge thank you to you, the reader, for trusting me to share content with you.

52

52

BioPharm

OCTOBER 8, 2023

The significant growth of the biologic drug market, bolstered by the COVID-19 pandemic and the development of relevant vaccines, along with the growing complexity and fragility of biologic drugs, has led to a need for improved freezing and thawing methods. While biologic drugs are becoming more mainstream as the pharmaceutical industry focuses on their development, maintaining high yields becomes critical to enabling timely introduction to the market and ensuring sufficient supplies.

Vaccines 40

Vaccines 40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmExec

OCTOBER 8, 2023

Click the title above for a link to open the Pharmaceutical Executive October 2023 issue in an interactive PDF format.

52

52

BioPharm

OCTOBER 8, 2023

The biotechnology industry is both vast and complex, with sectors varying from agricultural to pharmaceutical. Regardless of the sector, the goal remains the same – benefiting society through the creation of pharmaceutical, diagnostic, agricultural, environmental, and other products that utilize living cells and cellular materials. These products demand the development of innovative bioprocessing techniques as well as advanced equipment that can support each stage in the flow.

40

40

BioPharm

OCTOBER 8, 2023

Grand River Aseptic Manufacturing (“GRAM”) needed commercial-scale, #ultralowtemperature capacity units at -50°C delivered immediately to store forthcoming raw materials. A typical timeline for these solutions can run months, which did not meet GRAM’s needs. Working with #FARRAR and creating cross-company project team enabled a typically long delivery cycle to be completed quickly and safely, with storage beginning 18 business days after the initial call (including a national holiday).

Communication 40

Communication 40

BioPharm

OCTOBER 8, 2023

Webinar Date/Time: Tue, Oct 31, 2023 11:00 AM EDT

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software